These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8084615)

  • 21. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.
    Lányi A; Deb D; Seymour RC; Ludes-Meyers JH; Subler MA; Deb S
    Oncogene; 1998 Jun; 16(24):3169-76. PubMed ID: 9671396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel homeodomain-interacting protein kinase family member, HIPK4, phosphorylates human p53 at serine 9.
    Arai S; Matsushita A; Du K; Yagi K; Okazaki Y; Kurokawa R
    FEBS Lett; 2007 Dec; 581(29):5649-57. PubMed ID: 18022393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cdk9 phosphorylates p53 on serine 392 independently of CKII.
    Claudio PP; Cui J; Ghafouri M; Mariano C; White MK; Safak M; Sheffield JB; Giordano A; Khalili K; Amini S; Sawaya BE
    J Cell Physiol; 2006 Sep; 208(3):602-12. PubMed ID: 16741955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases.
    Hu MC; Qiu WR; Wang YP
    Oncogene; 1997 Nov; 15(19):2277-87. PubMed ID: 9393873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Rift Valley fever virus nonstructural protein NSs is phosphorylated at serine residues located in casein kinase II consensus motifs in the carboxy-terminus.
    Kohl A; di Bartolo V; Bouloy M
    Virology; 1999 Oct; 263(2):517-25. PubMed ID: 10544123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Xenopus p53 is biochemically similar to the human tumour suppressor protein p53 and is induced upon DNA damage in somatic cells.
    Cox LS; Midgley CA; Lane DP
    Oncogene; 1994 Oct; 9(10):2951-9. PubMed ID: 8084598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of p53 quaternary structure in relation to sequence-specific DNA binding.
    Hainaut P; Hall A; Milner J
    Oncogene; 1994 Jan; 9(1):299-303. PubMed ID: 8302593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The DNA-binding and transcriptional activities of MAZ, a myc-associated zinc finger protein, are regulated by casein kinase II.
    Tsutsui H; Geltinger C; Murata T; Itakura K; Wada T; Handa H; Yokoyama KK
    Biochem Biophys Res Commun; 1999 Aug; 262(1):198-205. PubMed ID: 10448092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation by copper of p53 conformation and sequence-specific DNA binding: role for Cu(II)/Cu(I) redox mechanism.
    Hainaut P; Rolley N; Davies M; Milner J
    Oncogene; 1995 Jan; 10(1):27-32. PubMed ID: 7824276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphorylation of purified estradiol-liganded estrogen receptor by casein kinase II increases estrogen response element binding but does not alter ligand stability.
    Tzeng DZ; Klinge CM
    Biochem Biophys Res Commun; 1996 Jun; 223(3):554-60. PubMed ID: 8687434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs.
    Knippschild U; Milne DM; Campbell LE; DeMaggio AJ; Christenson E; Hoekstra MF; Meek DW
    Oncogene; 1997 Oct; 15(14):1727-36. PubMed ID: 9349507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New monoclonal antibodies recognizing p53 protein phosphorylated by casein kinase II at serine 392.
    Pospísilová S; Kanková K; Svitáková M; Nenutil R; Vojtesek B
    Folia Biol (Praha); 2001; 47(4):148-51. PubMed ID: 11508859
    [No Abstract]   [Full Text] [Related]  

  • 33. Signaling to p53: breaking the posttranslational modification code.
    Appella E; Anderson CW
    Pathol Biol (Paris); 2000 Apr; 48(3):227-45. PubMed ID: 10858956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphorylation of the C-terminal sites of human p53 reduces non-sequence-specific DNA binding as modeled with synthetic peptides.
    Hoffmann R; Craik DJ; Pierens G; Bolger RE; Otvos L
    Biochemistry; 1998 Sep; 37(39):13755-64. PubMed ID: 9753464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation.
    Kapoor M; Hamm R; Yan W; Taya Y; Lozano G
    Oncogene; 2000 Jan; 19(3):358-64. PubMed ID: 10656682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteolytic cleavage of p53 mutants in response to mismatched DNA.
    Mee T; Okorokov AL; Metcalfe S; Milner J
    Br J Cancer; 1999 Sep; 81(2):212-8. PubMed ID: 10496344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53.
    Milne DM; Palmer RH; Meek DW
    Nucleic Acids Res; 1992 Nov; 20(21):5565-70. PubMed ID: 1454521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence.
    Niewolik D; Vojtesek B; Kovarik J
    Oncogene; 1995 Mar; 10(5):881-90. PubMed ID: 7898929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes.
    Wolkowicz R; Elkind NB; Ronen D; Rotter V
    Oncogene; 1995 Mar; 10(6):1167-74. PubMed ID: 7535417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural and kinetic analysis of p53-DNA complexes and comparison of human and murine p53.
    Hall AR; Milner J
    Oncogene; 1995 Feb; 10(3):561-7. PubMed ID: 7845681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.